Presented By:
Becky Winslow, BS, PharmD
Speaker Biography:
Becky Winslow is an accomplished Doctor of Clinical Pharmacy with more than twenty years of clinical pharmacotherapy and pharmacy business operations experience, which includes seven years of direct patient-facing care, seven years of pharmacy management experience, and six years of experience as a medical science liaison in the pharmacogenomics field. Becky excels at developing and managing collaborative relationships with healthcare professionals and key opinion leaders to stay abreast of emerging trends and to achieve project goals. Becky is an articulate communicator with an extensive background in gathering and critically analyzing research and data, translating complex content into a level appropriate for the target audience, writing clinical and marketing material, presenting, teaching, and training. Becky has consulted on several notable pharmacogenomics endeavors, including training the consultant pharmacists in the “Know Your Rx Coalition,” consulting for Cedarville University’s Pharmacogenomics Excellence Program, and leading the project to integrate pharmacogenomics into Apollo Vanguard’s suite of employee benefits. Becky Winslow is a registered provider for the Test2Learn(TM) Community Pharmacogenomics Certificate Program and a member of both the Clinical Pharmacogenetics Implementation Consortium and the Get the Medications Right Institute. She is currently both the Senior Clinical Pharmacogenomics Specialist and the Fellowship Program Didactic Director in the Medical Affairs Department at Admera Health.
Webinar:
The Pharmacogenomics Behind the Investigational Treatments of COVID-19 and its High-Risk Underlying Conditions
Webinar Abstract:
As of May 4, 2020, 1,152,372 total COVID-19 cases and 67,456 total deaths have been reported in the United States (U.S.). Fifty-five U.S. jurisdictions have reported cases including the 50 states, the District of Columbia, Puerto Rico, Guam, the Northern Mariana Islands, and the U.S. Virgin Islands. According to the CDC, older adults and people of any age who have severe underlying medical conditions such as diabetes, chronic lung disease, cardiovascular disease, and any disease that causes the patient to be immunocompromised might be at higher risk for contracting and experiencing severe illness from COVID-19. Most patients with significant underlying chronic medical conditions take medications to mitigate their disease. Also, some patients take medicines that can induce immunosuppression and increase their chances of contracting COVID-19. Pharmacogenomics directed medication therapy management before infection with COVID-19 has the potential to reduce the chances of patients with chronic disease contracting COVID-19 and, it increases their chances for survival from COVID-19 should they become infected. COVID-19 is a novel coronavirus that, once contracted, manifests itself through a wide range of symptoms. The symptoms range anywhere between no signs of COVID-19 at all to death from COVID-19 induced pathophysiology. Many medications are currently proposed for treating COVID-19, and many drugs are now being used to treat COVID-19’s sequelae, such as acute respiratory distress syndrome, sepsis, and coagulopathy. Pharmacogenomics directed medication management also has the potential to improve the efficacy of and decrease the toxicity of some medications used to treat COVID-19 and its most common sequelae.
Earn PACE Credits:
1. Make sure you’re a registered member of LabRoots (
2. Watch the webinar on YouTube or on the LabRoots Website (
3. Click Here to get your PACE credits (Expiration date – MAY 05, 2022): (
LabRoots on Social:
Facebook:
Twitter:
LinkedIn:
Instagram:
Pinterest:
SnapChat: labroots_inc
